Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Objective To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment and after being switched from AD...

Full description

Bibliographic Details
Main Authors: Rieke Alten, Carol Cronenberger, Daniel F Alvarez, Amy E Bock, Ivana Vranic, Wuyan Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001578.full

Similar Items

Similar Items